Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
NCT00660036 · University of Pittsburgh · PHASE1 · terminated · last registry update 2016-01-15 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to new safety information” | Open Targets' class: safety sideeffects | Registry record, University of Pittsburgh |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD33 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-03-31Phase 3 first posted: University of Birmingham, Gemtuzumab ozogamicin + Liposomal daunorubicin (NCT02724163)
- 2016-01-27Phase 3 first posted: Actinium Pharmaceuticals, Iomab-B + Conventional Care (NCT02665065)
- 2015-06-16Phase 3 first posted: Versailles Hospital, Gemtuzumab ozogamicin (GO) (NCT02473146)
- 2015-04-22Also stopped (terminated): New York Medical College, Gemtuzumab Ozogamicin + Busulfan (NCT00669890)
- 2015-02-06Results posted on the registry: National Cancer Institute (NCI), vorinostat + gemtuzumab ozogamicin (NCT00895934)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision